Duckbill Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 8.70 M
- Company Age 30 Year, 8 Months
- Last Filing with ROC 31 Mar 2020
- Satisfied Charges ₹ 8.15 Cr
- Revenue Growth -1.51%
- Profit Growth -0.11%
- Ebitda -2.93%
- Net Worth 11.86%
- Total Assets -0.22%
About Duckbill Drugs
Duckbill Drugs Pvt Ltd (DDPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 19 May 1994 and has a history of 30 years and eight months. Its registered office is in Kolkata, West Bengal, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 8.70 M.
The company has closed loans amounting to ₹8.15 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Asoke Paul, Reeta Paul, Sangita Paul, and One other member serve as directors at the Company.
Company Details
-
Location
Kolkata, West Bengal, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232WB1994PTC063258
-
Company No.
063258
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 May 1994
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Kolkata
Industry
Who are the key members and board of directors at Duckbill Drugs?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Asoke Paul
|
Additional Director | 30-Mar-2023 | Current |
|
Reeta Paul
|
Additional Director | 30-Mar-2023 | Current |
|
Sangita Paul
|
Additional Director | 30-Mar-2023 | Current |
|
Tapan Paul
|
Additional Director | 30-Mar-2023 | Current |
Financial Performance of Duckbill Drugs.
Duckbill Drugs Pvt Ltd, for the financial year ended 2020, experienced Minor drop in revenue, with a 1.51% decrease. The company also saw a slight decrease in profitability, with a 0.11% decrease in profit. The company's net worth Soared by an impressive increase of 11.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Duckbill Drugs?
In 2020, Duckbill Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹8.15 Cr
Charges Breakdown by Lending Institutions
- Punjab National Bank : 2.99 Cr
- State Bank Of India : 2.96 Cr
- The Federal Bank Limited : 2.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 18 Oct 2011 | State Bank Of India | ₹1.88 Cr | Satisfied |
| 05 Mar 2009 | Punjab National Bank | ₹2.99 Cr | Satisfied |
| 06 Mar 2006 | The Federal Bank Limited | ₹2.20 Cr | Satisfied |
| 19 Jul 2003 | State Bank Of India | ₹1.08 Cr | Satisfied |
How Many Employees Work at Duckbill Drugs?
Duckbill Drugs has a workforce of 58 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Duckbill Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Duckbill Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
